The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil/lymphocyte ratio (NLR) may predict prognostic factor with gemcitabine/cisplatin/S-1 (GCS) for patients with advanced biliary tract cancer (MITSUBA /KHBO1401-1B).
 
Toru Otsuru
No Relationships to Disclose
 
Tatsuya Ioka
Honoraria - Daiichi Sankyo; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Otsuka; Shire; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Mochida Pharmaceutical Co. Ltd.; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Baxalta/Shire (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Taiho Pharmaceutical; Taiho Pharmaceutical (Inst)
 
Hiroaki Nagano
Speakers' Bureau - Kaken Pharmaceutical; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Etsuro Hatano
Consulting or Advisory Role - Lilly
Speakers' Bureau - Taiho Pharmaceutical
 
Hidetoshi Eguchi
No Relationships to Disclose
 
Masashi Kanai
Speakers' Bureau - Taiho Pharmaceutical
 
Shogo Kobayashi
No Relationships to Disclose
 
Satoru Seo
Research Funding - Panasonic
 
Hideo Baba
Honoraria - Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Akinobu Taketomi
Research Funding - Lilly; Taiho Pharmaceutical (Inst)
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical; Takeda